Can I read P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data on EtoBox?

P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data by Kott, A.; Daniel, D.G. is a Medicine article available to read on EtoBox.

What is P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data about?

Introduction: Anaemia is common in haemodialysis patients and treating it with erythropoiesis-stimulating agents (ESAs) is complex due to many factors. Objectives: To assess the usefulness of the anaemia control model (ACM) in the treatment of anaemia in haemodialysis. Methods: ACM is a software that predicts the optimal dose of darbepoetin and iron sucrose to achieve target haemoglobin (Hb) and ferritin levels, and makes prescription suggestions. Study conducted in dialysis clinics lasting 18 months with two intervention phases (IPs) with ACM (IP1, n: 213; IP2, n: 218) separated by a control phase (CP, n: 219). The primary outcome was the percentage of Hb in range and the median dose of ESAs, and the secondary outcomes were transfusion, hospitalisation and cardiovascular events. Clinical and patient analyses were performed. Hb variability was assessed by the standard deviation (SD) of the Hb. We also analysed the patients with most of the suggestions confirmed (ACM compliant group). Results: ACM increased the percentage of Hb in range: 80.9% in IP2, compared with 72.7% in the CP and reduced the intake of darbepoetin (IP1: 20 [70]; CP 30 [80] g, p = 0.032) with less Hb fluctuation

Who reads P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data?

Author

Kott, A.; Daniel, D.G.

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0924-977X)

Published

2020

Language

EN

Field

Medicine (Life Sciences)